07:05 AM EDT, 08/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target price to USD40 (USD43), implying 9x our 2025 EPADS estimate, implying a 2025 P/E of 9x, which is largely in line with its three-year historical forward P/E average. The valuation balances the growth opportunity from Specialty Medicines segment with the concern on Vaccine segment as well as the heightened policy risk, notably in the U.S. GSK provided an overall good set of Q2 numbers in our view with sales beating consensus and favorable product mix and cost control lifting margin. For the full year, GSK now expects to hit the top end of its guidance range, though estimated currency headwinds appear larger. Overall, we expect revenue to be supported by key products in Specialty Medicines with GSK expecting the segment to contribute more than 50% of sales by 2031 (2024: 38%), while recent acquisitions provide a much-needed boost to its growth and drug pipeline in our view. We adjust our 2025 EPADS estimate to GBP3.30 from GBP3.40, and keep 2026's GBP3.70.